Quarterly report pursuant to Section 13 or 15(d)

Major Customers, Partnerships and Strategic Alliances (Tables)

v3.7.0.1
Major Customers, Partnerships and Strategic Alliances (Tables)
3 Months Ended
Mar. 31, 2017
Bioverativ Inc [Member]  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement

Revenues recognized under the agreement with Bioverativ for the three months ended March 31, 2017 and 2016 were as follows (in thousands):

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2017

 

 

2016

 

Revenue related to Bioverativ Collaboration:

 

 

 

 

 

 

 

 

Recognition of upfront fee

 

$

442

 

 

$

608

 

Research services

 

 

1,709

 

 

 

2,031

 

Total

 

$

2,151

 

 

$

2,639

 

 

Shire AG [Member]  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement

Revenues recognized under the agreement with Shire for the three months ended March 31, 2017 and 2016 were as follows (in thousands):

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2017

 

 

2016

 

Revenue related to Shire Collaboration:

 

 

 

 

 

 

 

 

Recognition of upfront fee

 

$

583

 

 

$

542

 

Research services

 

 

107

 

 

 

429

 

Total

 

$

690

 

 

$

971

 

 

Sigma-Aldrich Corporation [Member]  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement

Revenues recognized under the agreement with Sigma for the three months ended March 31, 2017 and 2016 were as follows (in thousands):

 

 

 

Three months ended

 

 

 

March 31,

 

 

 

2017

 

 

2016

 

Revenue related to Sigma Collaboration:

 

 

 

 

 

 

 

 

Royalty revenues

 

$

32

 

 

$

12

 

License fee revenues

 

 

267

 

 

 

7

 

Total

 

$

299

 

 

$

19